Ignite Creation Date:
2024-05-06 @ 8:14 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06302699
Status:
RECRUITING
Last Update Posted:
2024-03-12
First Post:
2024-03-04
Brief Title:
Detecting Minimal Residual Diseases MRD and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection UCAD in Multiple Myeloma
Sponsor:
Institute of Hematology Blood Diseases Hospital China
Organization:
Institute of Hematology Blood Diseases Hospital China
Study Overview
Official Title:
Clinical Utility of Ultrasensitive Chromosomal Aberrations Detection UCAD for Detecting Minimal Residual Disease MRD and Monitoring Clonal Evolution by Low-Pass Whole Genome Sequencing in Multiple Myeloma
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The presence of minimal residual disease MRD is an important prognostic factor for multiple myeloma while copy number variation CNV is a widely accepted biomarker used for multiple myeloma MM Detecting MRD and monitoring clonal evolution by monitoring CNV using low-pass whole genome sequencing is promising due to its high analytical sensitivity To evaluate the correlation between MRD detected by flow cytometry and low-pass whole genome sequencing nearly 200 samples were collected for this study We applied ultrasensitive chromosomal aberrations detection to detect CNV for each patient The follow-up samples were then collected and sequencing used the same method
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None